ArticleAntimicrobial agents and chemotherapy2006
EDTA as an adjunct antifungal agent for invasive pulmonary aspergillosis in a rodent model.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- High throughput screen reveals four compounds with novel antifungal activity, including a metal-responsive candidate with in vivo efficacy against Candida albicans.Scientific reports · 2026Article
- Type I Interferons Ameliorate Zinc Intoxication of Candida glabrata by Macrophages and Promote Fungal Immune Evasion.iScience · 2020Article
- TargetingInternational journal of molecular sciences · 2019Article
- A Novel Polyaminocarboxylate Compound To Treat Murine Pulmonary Aspergillosis by Interfering with Zinc Metabolism.Antimicrobial agents and chemotherapy · 2018Article
- Novel Zinc-Attenuating Compounds as Potent Broad-Spectrum Antifungal Agents withAntimicrobial agents and chemotherapy · 2018Article
- The Semi-Synthetic Peptide Lin-SB056-1 in Combination with EDTA Exerts Strong Antimicrobial and Antibiofilm Activity against Pseudomonas aeruginosa in Conditions Mimicking Cystic Fibrosis Sputum.International journal of molecular sciences · 2017Article
- In vitro and in vivo activity of EDTA and antibacterial agents against the biofilm of mucoid Pseudomonas aeruginosa.Infection · 2017Article
- Rodent Models of Invasive Aspergillosis due toFrontiers in microbiology · 2017Review
- Metal Chelation as a Powerful Strategy to Probe Cellular Circuitry Governing Fungal Drug Resistance and Morphogenesis.PLoS genetics · 2016Article
- Presence of Candida albicans in Root Canals of Teeth with Apical Periodontitis and Evaluation of their Possible Role in Failure of Endodontic Treatment.Journal of international oral health : JIOH · 2015Article
- Targeting zinc homeostasis to combat Aspergillus fumigatus infections.Frontiers in microbiology · 2015Article
- Zinc acquisition: a key aspect in Aspergillus fumigatus virulence.Mycopathologia · 2014Review
- HapX-mediated adaption to iron starvation is crucial for virulence of Aspergillus fumigatus.PLoS pathogens · 2010Article
- SreA-mediated iron regulation in Aspergillus fumigatus.Molecular microbiology · 2008Article
- Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture.Antimicrobial agents and chemotherapy · 2008Article
- Factors affecting antimicrobial activity of MUC7 12-mer, a human salivary mucin-derived peptide.Annals of clinical microbiology and antimicrobials · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rats immunosuppressed by the administration of cyclophosphamide and cortisone acetate and then infected with Aspergillus fumigatus were treated with an antifungal drug, EDTA, or a combination of one of the antifungal agents, amphotericin B lipid complex (ABLC; 5 mg/kg of body weight/day for 7 days), and EDTA (30 mg/kg/day for 7 days). The mortality rate was reduced, the duration of survival was increased, fewer A. fumigatus organisms were recovered from the lungs, and less-severe lung lesions were seen histopathologically in the rats receiving the combination treatment than in the rats receiving either an antifungal agent or EDTA alone. Further studies regarding the mechanisms of EDTA and its interactions with ABLC are warranted, and further studies are needed to more fully examine the safety, tolerance, and optimal dosing of EDTA in the treatment of this and other fungal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.